Last updated: September 17, 2026
Sanofi-Aventis U.S. LLC sued Sandoz Inc. in the U.S. District Court for the District of Delaware after Sandoz notified Sanofi of an abbreviated new drug application for a proposed insulin glargine product referencing Lantus. The case was a Hatch-Waxman patent dispute involving Sanofi’s insulin glargine formulation and related patent rights. The docket was assigned to Judge Richard G. Andrews under Case No. 1:15-cv-00415-RGA.
The dispute ended without a reported trial judgment or Federal Circuit merits decision. The case was resolved through a dismissal, and the material commercial terms of the parties’ resolution were not publicly disclosed in the reported docket materials. The related Lantus patent estate was later weakened by Federal Circuit precedent holding key Sanofi insulin glargine claims obvious. (Sanofi-Aventis U.S. LLC v. Sandoz, Inc., No. 1:15-cv-00415-RGA, D. Del.; Sanofi-Aventis U.S. LLC v. Mylan GmbH, 791 F.3d 1368 (Fed. Cir. 2015).)
What drug and product were involved in Sanofi v. Sandoz?
The litigation concerned insulin glargine, the active ingredient in Sanofi’s Lantus product.
| Item |
Details |
| Reference drug |
Lantus |
| Active ingredient |
Insulin glargine |
| Reference sponsor |
Sanofi-Aventis U.S. LLC |
| Proposed product sponsor |
Sandoz Inc. |
| Regulatory pathway |
Abbreviated new drug application, or ANDA |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:15-cv-00415-RGA |
| Filing year |
2015 |
| Litigation framework |
Hatch-Waxman Act |
| Patent technology |
Insulin glargine formulations and related treatment claims |
Lantus is a long-acting basal insulin. The formulation uses insulin glargine in an acidic solution and includes excipients such as zinc and m-cresol. Sanofi’s patent strategy focused on the composition and stability of the formulation rather than on composition-of-matter protection for insulin glargine itself.
Sandoz’s ANDA filing triggered a patent dispute because the proposed product was intended to be approved as a generic equivalent of Lantus. The case was not a biosimilar action under the modern BPCIA framework. Lantus was approved as an NDA product, and the dispute proceeded under the ANDA provisions of the Hatch-Waxman Act.
What patents protected Lantus in the Sandoz case?
The principal patent family associated with the Lantus insulin glargine litigation included U.S. Patent Nos. 7,713,930 and 8,603,044.
| Patent |
General subject matter |
Litigation significance |
| U.S. Patent No. 7,713,930 |
Insulin glargine pharmaceutical formulations |
Core formulation patent asserted against generic insulin glargine products |
| U.S. Patent No. 8,603,044 |
Insulin glargine treatment and formulation-related claims |
Related patent asserted in parallel Lantus litigation |
| Device and delivery patents |
SoloSTAR pen and injection-device technology |
Potentially relevant to pen-based products, but not the primary focus of the reported Sandoz case |
The ’930 patent covered formulations containing insulin glargine and specified excipient conditions. Sanofi relied on this type of patent protection because the basic insulin glargine molecule had limited remaining exclusivity by the time of the 2015 disputes.
The ’044 patent was part of the same broader Lantus patent campaign. The exact asserted claims and claim-by-claim litigation positions must be distinguished from the separate Sanofi v. Mylan action, where both patents were litigated to a reported Federal Circuit decision.
When did Sanofi file the case against Sandoz?
Sanofi filed the action in 2015 after receiving Sandoz’s paragraph IV notice concerning its proposed insulin glargine product. The case number indicates that it was the 415th civil action filed in the District of Delaware in 2015.
The procedural sequence was typical of a Hatch-Waxman action:
- Sandoz submitted an ANDA for an insulin glargine product referencing Lantus.
- Sandoz provided a paragraph IV certification asserting that relevant Sanofi patents were invalid, unenforceable, or not infringed.
- Sanofi filed a patent-infringement complaint.
- The filing triggered the statutory stay of FDA approval applicable to Hatch-Waxman litigation.
- The parties resolved the action before a reported merits trial judgment.
The public record does not establish a reported claim-construction ruling, trial verdict, or final appellate decision specific to the Sandoz docket.
What was the litigation status and outcome?
The case did not produce a published opinion deciding the validity or infringement of the asserted patents against Sandoz’s specific product.
The reported outcome was dismissal pursuant to the parties’ resolution. The public docket does not disclose all commercial terms, including:
- Any permitted launch date for Sandoz;
- Whether Sandoz received a license;
- Whether the settlement included a contingent launch provision;
- Whether Sandoz agreed to manufacturing or labeling restrictions;
- Whether the agreement included acceleration, supply, or royalty provisions.
A dismissal with prejudice resolves the case between the parties but does not independently establish that the asserted patents were valid or infringed. It also does not prevent later invalidity attacks by other generic manufacturers.
Did Sandoz file a Paragraph IV challenge?
Yes. The action arose from a paragraph IV certification connected to Sandoz’s ANDA for a Lantus-referencing insulin glargine product.
A paragraph IV certification is a statutory assertion that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. It creates the basis for the reference-drug sponsor to sue before FDA approval.
The paragraph IV mechanism also creates a potential 180-day first-filer exclusivity period for the first qualifying generic applicant. The public record for this case does not establish whether Sandoz was the first paragraph IV filer for the relevant Lantus patents or whether it retained any first-filer exclusivity.
What was the impact of the Sanofi v. Mylan decision on the Sandoz case?
The Federal Circuit’s decision in Sanofi-Aventis U.S. LLC v. Mylan GmbH materially weakened Sanofi’s position in related Lantus patent litigation.
In that case, the Federal Circuit affirmed the invalidity of claims in the ’930 and ’044 patents on obviousness grounds. The court analyzed whether the claimed insulin glargine formulations and treatment methods would have been obvious in light of the prior art. The decision reduced the ability of Sanofi to use those patents as a broad barrier against generic insulin glargine products. (Sanofi-Aventis U.S. LLC v. Mylan GmbH, 791 F.3d 1368 (Fed. Cir. 2015).)
The Mylan ruling did not automatically dispose of the Sandoz case. Patent invalidity is ordinarily determined on the record developed in each case, and different parties may raise different defenses. The decision nevertheless created substantial litigation pressure because:
- The same or closely related patent claims were vulnerable to the same obviousness arguments.
- A later district court would face binding Federal Circuit precedent on the relevant legal issues.
- Sanofi’s settlement leverage was reduced if the principal formulation claims were difficult to defend.
- Sandoz could use the ruling to support a noninfringement or invalidity position in settlement negotiations.
What was the Orange Book status of Lantus?
Lantus was approved under an NDA and was subject to Orange Book patent listing. The relevant Lantus patent estate included formulation patents and, depending on the product presentation, patents relating to delivery devices and injector systems.
The Orange Book listing had commercial importance because a listed patent can trigger Hatch-Waxman litigation after an ANDA applicant submits a paragraph IV certification. The listing does not establish that the patent is valid or infringed. It provides the procedural basis for litigation.
The core Lantus formulation patents had expiration dates in the 2020s, subject to patent-term adjustment and any applicable regulatory extensions. Their practical value depended on whether the claims survived obviousness challenges and whether a generic product could avoid the listed claims through formulation, labeling, or device design.
Did the case involve formulation patents or method-of-use patents?
The litigation was principally associated with formulation protection.
Formulation patents
Formulation claims were directed to the composition of the insulin glargine product, including:
- Insulin glargine concentration;
- Acidic pH conditions;
- Zinc content;
- Preservatives such as m-cresol;
- Stability and storage characteristics;
- Pharmaceutical carrier components.
Formulation patents are important in insulin litigation because a generic applicant may not need to copy every commercial characteristic of the reference product. A design-around may be possible if the proposed formulation provides equivalent therapeutic performance while avoiding a specific concentration, excipient, or pH limitation.
Method-of-use patents
The related ’044 patent litigation included treatment-oriented claims. Method-of-use patents can create a separate infringement theory when a generic sponsor’s proposed labeling instructs physicians or patients to use the product in a patented manner.
Generic applicants often attempt to reduce method-of-use exposure through skinny labeling. That approach removes patented indications or instructions from the proposed label. Its effectiveness depends on whether the remaining label, promotional conduct, or ordinary use still supports induced-infringement allegations.
How strong was Sanofi’s Lantus patent estate?
The Lantus patent estate was commercially important but legally vulnerable.
| Strength factor |
Assessment |
| Core molecule protection |
Limited by the age of insulin glargine and the timing of the litigation |
| Formulation protection |
Significant commercial value, but exposed to obviousness challenges |
| Method-of-use protection |
Potentially useful, but dependent on label language and induced-infringement proof |
| Device protection |
Could delay copying of SoloSTAR presentations, but not necessarily generic vial or alternate-pen entry |
| Litigation precedent |
Adverse Federal Circuit ruling weakened key formulation and treatment claims |
| Settlement leverage |
Reduced after invalidity findings in related litigation |
| Manufacturing barrier |
Moderate; insulin production and formulation require technical capability, but patent protection was not the only barrier |
The strongest practical barriers were likely regulatory manufacturing requirements, insulin quality controls, device compatibility, and supply-chain validation. These barriers can delay entry even when patent rights are weak. They do not, however, provide the same legal exclusion as a valid and enforceable patent.
What generic entry risks existed for Sanofi?
The principal entry scenarios were:
- Settlement-authorized entry. Sandoz could receive a negotiated launch date before the last asserted patent expired.
- Patent invalidity. Sandoz could obtain approval and launch if the relevant claims were held invalid.
- Noninfringing design-around. Sandoz could use a formulation or delivery system outside the asserted claims.
- Post-expiration entry. Sandoz could enter after statutory patent and regulatory exclusivity ended.
- Commercial delay without patent exclusion. Manufacturing, inspection, approval, or supply problems could postpone launch even after legal clearance.
The Federal Circuit’s ruling in the Mylan litigation increased the probability that generic competitors could challenge the Lantus formulation estate successfully. Sanofi therefore faced a risk of multiple generic or follow-on insulin glargine products entering after the relevant regulatory and patent barriers were removed.
How did Lantus compare with competing insulin glargine products?
The principal competitive threat was not limited to traditional chemical generics. Insulin products also faced follow-on biologic competition and interchangeable insulin products.
| Product |
Sponsor |
Competitive position |
| Lantus |
Sanofi |
Originator insulin glargine product |
| Basaglar |
Eli Lilly and Boehringer Ingelheim |
Follow-on insulin glargine product approved through an abbreviated pathway |
| Semglee |
Biocon Biologics and Viatris |
Insulin glargine product later approved as interchangeable |
| Toujeo |
Sanofi |
Higher-concentration insulin glargine product with separate formulation and product positioning |
Basaglar entered the U.S. market in 2016, demonstrating that competition could reach the market while some Lantus-related patent disputes remained active. The existence of separate insulin glargine presentations also limited Sanofi’s ability to rely on a single patent family for all commercial products.
Did the case involve a licensing deal or settlement agreement?
The case was resolved, but the public docket does not provide a complete set of settlement terms. There is no reported public agreement establishing a comprehensive license covering all Sanofi insulin glargine patents and products.
The resolution should therefore be treated as a case-specific disposition rather than as evidence of a broad public cross-license. Any permitted Sandoz launch date, royalty arrangement, or manufacturing restriction would need to be established from nonpublic settlement documentation or later regulatory and commercial records.
What is the business significance of the case?
Sanofi v. Sandoz illustrates the limitations of secondary patent protection for mature insulin products. Formulation patents can extend the litigation life of a product after molecule-level exclusivity has weakened, but their value depends on narrow claim language and prior-art defenses.
For Sanofi, the case involved three risks:
- Loss of exclusivity for a high-revenue basal insulin product;
- Erosion of pricing power from follow-on insulin glargine products;
- Reduced settlement leverage after adverse precedent against related patent claims.
For Sandoz, the case offered a path to market but also involved substantial technical and regulatory obligations. Insulin products require validated manufacturing processes, tight potency and impurity controls, device or container compatibility, and reliable commercial supply. Patent clearance alone would not guarantee a successful launch.
Key Takeaways
- Sanofi sued Sandoz in the District of Delaware in 2015 over an ANDA for an insulin glargine product referencing Lantus.
- The dispute involved Sanofi’s Lantus formulation and related treatment patent estate.
- The case ended through a dismissal without a reported merits decision against Sandoz.
- The public docket does not disclose the material commercial terms of the resolution.
- The Federal Circuit’s 2015 Mylan decision invalidating related Sanofi patent claims weakened the Lantus patent estate.
- Lantus faced both traditional ANDA competition and follow-on insulin competition.
- Manufacturing complexity remained a practical barrier, but it did not replace patent exclusivity.
- The litigation reduced Sanofi’s ability to use formulation patents as a durable barrier to insulin glargine entry.
FAQs About Sanofi v. Sandoz 1:15-cv-00415
Was Sanofi v. Sandoz a biosimilar lawsuit?
No. The action proceeded under the Hatch-Waxman framework because the proposed product referenced an NDA-approved insulin product. It was not a BPCIA biosimilar action.
Did Sandoz win the case?
The docket does not report a merits judgment declaring Sandoz’s product noninfringing or Sanofi’s patents invalid. The case was resolved through dismissal.
Did Sanofi’s Lantus patents survive?
Some Lantus-related claims were challenged in separate litigation. The Federal Circuit affirmed invalidity findings concerning claims in the ’930 and ’044 patents in the Mylan litigation.
Did the lawsuit prevent generic insulin glargine entry?
It delayed or complicated Sandoz’s product pathway, but it did not prevent broader insulin glargine competition. Basaglar and later products entered the U.S. market through separate regulatory and commercial pathways.
Was Sandoz allowed to launch its insulin glargine product?
The public docket does not establish a definitive launch date or disclose the complete settlement terms governing any Sandoz launch.
References
- Sanofi-Aventis U.S. LLC v. Sandoz, Inc., No. 1:15-cv-00415-RGA, U.S. District Court for the District of Delaware, 2015-2016 docket.
- Sanofi-Aventis U.S. LLC v. Mylan GmbH, 791 F.3d 1368 (Fed. Cir. 2015).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2016). Basaglar approval and insulin glargine regulatory materials. FDA.
